Literature DB >> 10629244

Pharmacokinetics and pharmacodynamics of moist snuff in humans.

R V Fant1, J E Henningfield, R A Nelson, W B Pickworth.   

Abstract

INTERVENTION: Four brands of moist snuff and a non-tobacco mint snuff were tested. Subjects reported to the laboratory for five experimental sessions. After baseline measurement of dependent variables, each subject placed 2 g of one of the brands of snuff (or one Skoal Bandits pouch) between the cheek and gum for 30 minutes. The subjects remained in the experimental laboratory for an additional 60 minutes.
SUBJECTS: Ten volunteers who were daily users of smokeless tobacco. MAIN OUTCOME MEASURES: Plasma nicotine concentration, cardiovascular effects, and subjective effects.
RESULTS: Large amounts of nicotine were delivered rapidly to the bloodstream. The amount of nicotine absorbed and the rate of absorption were related to the pH of the snuff product in aqueous suspension. Cardiovascular and subjective effects were related to the amount of nicotine absorbed.
CONCLUSIONS: Snuff products are capable of rapidly delivering high doses of nicotine, which can lead to dependence. Long-term use of snuff can lead to a number of adverse health effects including oral cancers, cardiovascular diseases, and gingival diseases. For these reasons, it is important that the public health community considers oral snuff use as a burden on public health in the same way that cigarette smoking is recognised.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10629244      PMCID: PMC1759743          DOI: 10.1136/tc.8.4.387

Source DB:  PubMed          Journal:  Tob Control        ISSN: 0964-4563            Impact factor:   7.552


  38 in total

1.  A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects.

Authors:  Andrea R Vansickel; Caroline O Cobb; Michael F Weaver; Thomas E Eissenberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology.

Authors:  Jennifer N Gray; Alison B Breland; Michael Weaver; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2008-09       Impact factor: 4.244

3.  Characteristics of "American Snus" and Swedish Snus Products for Sale in Massachusetts, USA.

Authors:  Andrew B Seidenberg; Olalekan A Ayo-Yusuf; Vaughan W Rees
Journal:  Nicotine Tob Res       Date:  2018-01-05       Impact factor: 4.244

4.  Assessing Constituent Levels in Smokeless Tobacco Products: A New Approach to Engaging and Educating the Public.

Authors:  Eugene Borgida; Barbara Loken; Allison L Williams; Joseph Vitriol; Irina Stepanov; Dorothy Hatsukami
Journal:  Nicotine Tob Res       Date:  2015-01-29       Impact factor: 4.244

5.  Chemical characterization of domestic oral tobacco products: total nicotine, pH, unprotonated nicotine and tobacco-specific N-nitrosamines.

Authors:  Tameka S Lawler; Stephen B Stanfill; Liqin Zhang; David L Ashley; Clifford H Watson
Journal:  Food Chem Toxicol       Date:  2013-03-19       Impact factor: 6.023

6.  Smokeless Tobacco and Stroke - A Clinico-epidemiological Follow-up Study in A Tertiary Care Hospital.

Authors:  Subhransu Sekhar Jena; Shobhitendu Kabi; Baikuntha Nath Panda; B C Kameswari; Ishwar Chandra Behera; Subrat Kumar Tripathy; Seemanchana Mahanta
Journal:  J Clin Diagn Res       Date:  2016-10-01

7.  Monitoring tobacco-specific N-nitrosamines and nicotine in novel Marlboro and Camel smokeless tobacco products: findings from Round 1 of the New Product Watch.

Authors:  Irina Stepanov; Lois Biener; Aleksandar Knezevich; Amy L Nyman; Robin Bliss; Joni Jensen; Stephen S Hecht; Dorothy K Hatsukami
Journal:  Nicotine Tob Res       Date:  2011-10-29       Impact factor: 4.244

Review 8.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 9.  Clinical trials methods for evaluation of potential reduced exposure products.

Authors:  Dorothy K Hatsukami; Karen Hanson; Anna Briggs; Mark Parascandola; Jeanine M Genkinger; Richard O'Connor; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 10.  Effect of smokeless tobacco (snus) on smoking and public health in Sweden.

Authors:  J Foulds; L Ramstrom; M Burke; K Fagerström
Journal:  Tob Control       Date:  2003-12       Impact factor: 7.552

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.